Telix Pharmaceuticals Limited
Contact: Mrs Crystal Eid
55 Flemington Road
About Telix Pharmaceuticals Limited
A clinical-stage biotechnology company dedicated to the development and commercialisation of molecurlarly-targeted radiation (MTR) therapy.
7 articles with Telix Pharmaceuticals Limited
Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.
Telix Pharmaceuticals and Cardinal Health Enter into Distribution Agreement for Prostate Cancer Imaging
Telix Pharmaceuticals (US) Inc. today announced that it has entered into a distribution agreement with Cardinal Health (NYSE:CAH).
Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that its partner Telix Pharmaceuticals Limited ("Telix") (ASX:TLX), has submitted a Clinical Trial Application (CTA) to initiate a Phase III trial in Europe for 89Zr-DFO-girentuximab (TLX250) for the imaging of renal (kidney) cancer with Positron Emission Tomography (PET).
Telix Pharmaceuticals Limited and Nihon Medi-Physics Co., Ltd. have today announced that they have entered into a memorandum of understanding (MOU) for a commercial partnership in renal cancer imaging for the Japanese market.
Telix Pharmaceuticals Limited is pleased to announce that Memorial Sloan Kettering Cancer Center (“MSK”) has imaged the first two patients in a 500 patient Phase II Expanded-Access Investigational New Drug (IND) study for imaging prostate cancer with the investigational agent 68Ga-PSMA-11
Telix Pharmaceuticals Limited has announced a technology transfer and manufacturing agreement with ISOLOGIC Innovative Radiopharmaceuticals
The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s products.